EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLS2 reshapes glycolytic metabolism and bioenergetic homeostasis in glioblastoma cells

Juan De Los Santos-Jiménez, José A Campos-Sandoval, Jessica Sudderth, Lauren G Zacharias, João Santos Patricio, Francisco J Alonso, Javier Márquez, Thomas P Mathews, Ralph J DeBerardinis, José M Matés

Pharmacological Reports · 14.10.2026

DOI: 10.1007/s43440-026-00908-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, online erschienen am 14.10.2026. Verfasst von Juan De Los Santos-Jiménez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, Málaga, Spain. jsj@uma.es. Hauptthemen laut MEDLINE: Glutaminase, Glioblastoma, Glycolysis, Energy Metabolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Howard Hughes Medical Institute Investigator Program and the National Cancer Institute, MICIU/AEI/10.13039/501100011033, European Social Fund Plus (ESF+).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) exhibits extensive metabolic reprogramming, including glucose and glutamine (Gln) addiction, with Gln being converted into glutamate by glutaminase, encoded by the GLS and GLS2 genes. GLS2 acts as a context-dependent tumor suppressor, although the underlying mechanisms remain poorly understood. GLS2 is silenced in GBM, and we previously showed that its re-expression modulates pyruvate dehydrogenase (PDH) activity and tricarboxylic acid cycle (TCAC) metabolism, suggesting a distinct metabolic rewiring associated with its tumor-suppressive function.

Methods

LN229 and T98G GBM cell lines were used as experimental models. Metabolomic profiling by liquid chromatography-mass spectrometry was performed to compare changes in central metabolic pathways following GLS2 or GLS overexpression. Glutaminase and PDH enzymatic activities were measured, and Western blotting was performed to assess GLS, GLS2, and PDHA1 protein levels and PDHA1 phosphorylation. A Seahorse analyzer was employed to quantify real-time ATP production derived from glycolysis and oxidative phosphorylation.

Results

Overexpression of GLS2, but not GLS, in LN229 cells caused the accumulation of TCAC-related metabolites, except for citrate, whose depletion is attributed to GLS2’s effect on PDH phosphorylation, causing reduced PDH activity. This was accompanied by decreased levels of several acyl-carnitines. Furthermore, GLS2 induced the accumulation of glucose/fructose, while reducing levels of glucose-6-phosphate and pentose-phosphates, consistent with altered glycolysis. GLS2 also diminished the ATP/AMP ratio, confirmed by a reduced ATP synthesis rate, particularly glycolytic ATP, whereas mitochondrial ATP production remained unaltered.

Conclusions

GLS2 exerts an isoenzyme-specific effect on Gln and glucose metabolism in GBM, likely modulating the glycolysis/pentose-phosphate pathway (PPP)-TCAC-axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutaminaseGlioblastomaGlycolysisEnergy MetabolismHomeostasisBrain NeoplasmsHumansCell Line, TumorGlucoseMetabolic ReprogrammingCitric Acid CycleGlutamine

Stichwörter der Autor:innen

Cancer metabolismGLS2GlioblastomaGlutaminaseGlutaminePyruvate dehydrogenase

Substanzen

GlutaminaseGLS2 protein, humanGlucoseGlutamine

Autor:innen und Institutionen

  • Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, Málaga, Spain. jsj@uma.es.
  • Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma BIONAND), Universidad de Málaga, Málaga, Spain. jsj@uma.es.
  • Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain. jsj@uma.es.
  • GENYO. Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain. jsj@uma.es.
  • Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Granada, Spain. jsj@uma.es.
  • Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, Málaga, Spain.

Förderung

  • Howard Hughes Medical Institute Investigator Program and the National Cancer Institute
  • MICIU/AEI/10.13039/501100011033
  • European Social Fund Plus (ESF+)
  • NCI NIH HHS
  • Cancer Prevention Research Institute of Texas
  • Ministerio de Ciencia e Innovación of Spain

Zitieren

APA

De Los Santos-Jiménez, J., Campos-Sandoval, J. A., Sudderth, J., Zacharias, L. G., Santos Patricio, J., Alonso, F. J., Márquez, J., Mathews, T. P., DeBerardinis, R. J., & Matés, J. M. (2026). GLS2 reshapes glycolytic metabolism and bioenergetic homeostasis in glioblastoma cells. Pharmacological Reports. https://doi.org/10.1007/s43440-026-00908-9

Vancouver

De Los Santos-Jiménez J, Campos-Sandoval JA, Sudderth J, Zacharias LG, Santos Patricio J, Alonso FJ, et al. GLS2 reshapes glycolytic metabolism and bioenergetic homeostasis in glioblastoma cells. Pharmacological Reports. 2026. doi:10.1007/s43440-026-00908-9

BibTeX
@article{DeLosSantosJimnez2026,
  author = {De Los Santos-Jiménez, Juan and Campos-Sandoval, José A and Sudderth, Jessica and Zacharias, Lauren G and Santos Patricio, João and Alonso, Francisco J and Márquez, Javier and Mathews, Thomas P and DeBerardinis, Ralph J and Matés, José M},
  title = {GLS2 reshapes glycolytic metabolism and bioenergetic homeostasis in glioblastoma cells},
  journal = {Pharmacological Reports},
  year = {2026},
  doi = {10.1007/s43440-026-00908-9}
}
Kostenlos starten →